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Codependency: can it be the path to a motivational change regarding drug 
abuse? 
 
 
Abstract 1 
Nowadays, the consumption of psychoactive substances is becoming more and 2 
more important in scientific research, due to a bigger concern about the consequences 3 
of substance abuse disorders. These disorders affect not only the individual but also 4 
“the system” where he/she belongs (leading to something called “codependency” in 5 
several cases). 6 
These addictive behaviours are tremendously prejudicial and the abuser needs 7 
to make a commitment to change it and, hence, improve quality of life of everyone 8 
affected by them. To engage in treatment, very often the individuals need the support 9 
of a loved one who is crucial during the motivational change, through all the stages and 10 
to maintain abstinence.  11 
Several approaches include family members/concerned significant others of 12 
substance abusers in the rehabilitation process so as to make the reluctant patients 13 
engage in treatment and help them throughout the motivational stages, toward a 14 
complete control over the dependence. This way, they might be able to positively 15 
influence the prognosis associated with substance use disorders. 16 
 17 
Keywords: codependency; substance use disorders; motivational change; the 18 
Transtheoretical Model  19 
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1. Introduction  20 
We live in a world of changes and high velocity updates to our knowledge. 21 
Codependency is not a recent term but the importance given to it in the process of 22 
change of a drug user (DU) is definitely a new scenario in mental health. A “paradigm 23 
shift” can be the expression used when speaking about the new approaches regarding 24 
drug abuse and its treatment.[1] 25 
The context of family interactions and the social environment is the most 26 
important contributor to the growth of an individual, who can mature into healthy 27 
individuals when they grow up in well-functioning families or, oppositely, into 28 
problematic adults when there are weak emotional bonds and a stressful environment 29 
at home.[2] 30 
Historically, substance use disorders (SUDs) were viewed as individual-based 31 
problems, most effectively treated by focusing on the diagnosed individual. However, 32 
after several clinical trials showing the efficacy (and often superiority) of couple/family 33 
treatments for these addictive behaviours, the previous emphasis on the individual 34 
changed and has slowly given rise to a greater awareness of family members’ crucial 35 
roles in the aetiology, maintenance and long-term course of addictions – an upbeat 36 
discover about a more global community based approach which is more likely to induce 37 
not only patients but also their families to engage in and adhere to treatment.[1, 3, 4] 38 
 According to the United Nations Office on Drugs and Crime (UNODC), 39 
substance abuse is one of the most important concerns in our world, with the 2017 40 
World Drug Report stating that approximately a quarter of a billion people (5.3% of the 41 
global adult population aged 15-64 years) used drugs at least once in 2015. Even more 42 
alarming is the fact that about 29.5 million of those drug users (0.6% of the global adult 43 
population aged 15-64 years) were suffering from drug use disorders. Another 44 
worrisome rate is an estimated number of 190,900 premature drug related deaths 45 
(mostly due to overdose).[5] 46 
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 Compared to men, overall drug use remains lower among women – globally, 47 
men are three times more likely to use cannabis, cocaine or amphetamines. On the 48 
other hand, women are more likely to misuse prescription drugs, particularly opioids 49 
and tranquillizers.[5] 50 
 The World Health Organization defines substance abuse as “the harmful or 51 
hazardous use of psychoactive substances, including alcohol and illicit drugs” which 52 
“can lead to dependence syndrome - a cluster of behavioural, cognitive and 53 
physiological phenomena that develops after repeated substance use and that typically 54 
include a strong desire to take the drug, difficulties in controlling its use, persisting in its 55 
use despite harmful consequences, a higher priority given to drug use than to other 56 
activities and obligations, increased tolerance and sometimes a physical withdrawal 57 
state”.[6]  58 
Seen as a chronic multifactorial disease, which causes considerable individual, 59 
family and social disruptions, a SUD can lead to misery of thousands of people. It is 60 
considered as a “bio-psycho-social problem”, affecting all aspects of life and its quality, 61 
with a huge impact not only in psychological (depression, anxiety, hopelessness, 62 
isolation) and physical health, but also economic, cultural and social effects. It 63 
becomes the priority over all the activities the individual used to do, sometimes 64 
representing an unhealthy attempt to manage problems. Its treatment (a difficult route 65 
with high numbers of dropouts and relapse episodes) should consist of an 66 
interdisciplinary approach from psychotherapeutic and social interventions aimed at 67 
rehabilitation and social reintegration of drug addicts.[3, 7-9]  68 
  Having all this in consideration, some questions came up: How does substance 69 
abuse affect the individual and the family? How can the family be an important part of 70 
the diagnosed individual’s treatment and abstinence? Are there any possible barriers to 71 
the implementation of this new family/relatives approach? What can be done in the 72 
future?  73 
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The influence of SUDs to the family/concerned significant others (CSOs) 74 
Over the past few years, it has become clearly evident SUDs and family 75 
problems very often coexist and a loved one's alcohol/drug abuse can seriously affect 76 
the lives of family and friends – creating a burden for the whole environment that 77 
surrounds the user. These adverse effects include [3, 4, 8, 10-18]: 78 
- Emotional load (wide range of feelings like anger, sadness, helplessness, 79 
frustration, denial, fear, worry, anxiety, depression, shame, guilt); 80 
- Economic problems (money diverts to buy substances, unemployment); 81 
- Social burden (medical conditions, homelessness, criminality); 82 
- Relationship dissatisfaction and distress (leads to isolation); 83 
- Family conflicts and instability (verbal assaults, physical violence); 84 
- Deleterious consequences on children (risk for neglect/abuse, poor 85 
academic performance, future substance abuse). 86 
 87 
Therefore, it is crucial to give the family/CSOs coping skills training and 88 
alternatives to arguing with or nagging the consumer - actions usually related to an 89 
increase of aggression. Also, the way relatives answer to consuming and non-90 
consuming behaviours is something worth examining.[11, 18] 91 
However, the link between SUD and relationship problems (such as poor 92 
communication, arguing, financial and other stressors)  is not unidirectional but rather a 93 
“reciprocal causality” where each can be a precursor to the other, creating a “vicious 94 
cycle” and one of the main reasons for bad outcomes and relapses after treatment.[3] 95 
 96 
It is estimated that, in 2015, around 17 million "healthy" years of life were lost 97 
(disability-adjusted life years or DALYs) due to SUDs – an increase of 24% when 98 
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compared to 2005 – showing the huge need for a change regarding treatment. There 99 
continues to be a large "treatment gap" worldwide - only one out of six people with drug 100 
use disorders is provided with treatment each year, making it clear that the accessibility 101 
of services for such conditions is limited on a global level.[5] 102 
The chronic nature of this addictive behaviour makes the relapse not only 103 
possible but likely to occur. As a consequence, the treatment is not believed to be 104 
effective since the prevalence of relapse is high, ranging from 60% to more than 85% 105 
within one year.[19-23] 106 
Unfortunately, it is usual for individuals with SUDs to be opposed to getting 107 
treatment leading their loved-ones to difficult situations when they have to choose 108 
between staying with them or detaching – with the purpose of encouraging the user to 109 
seek treatment. This influence of CSOs have shown great results and it is now 110 
considered essential in the (usually difficult) process of change.[4, 11, 24, 25] 111 
Several factors influence the demand for treatment and its adherence. Among 112 
them, there is one whose importance is huge: the addict’s motivation. This can be 113 
characterized as “a state of readiness or willingness to change the problematic 114 
behaviour”. Being motivated to change is critical to an individual’s performance, 115 
whether he is recognizing the need for change, seeking treatment, recovering or 116 
maintaining the abstinence and it will influence the outcome – it has the potential to 117 
enhance engagement and commitment, leading to a better prognosis.[7, 21, 26] 118 
 The CSO often has the unique ability to encourage/discourage the substance 119 
use with just a modest change in his own behaviour (if well applied, reinforcements are 120 
considered very useful). It is essential to know how to use positive reinforcement – 121 
providing support. This positive reinforcement (used only when the user is sober) has 122 
to be as seen as a “reward”, something powerful enough to be chosen over 123 
consuming.[11, 21]  124 
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 In addition to this positive reinforcement, the CSO should also be taught how 125 
not to enable or reward any behaviour related to the SUD and to avoid contact 126 
whenever he/she is consuming. Any action that could unintentionally be a support for 127 
the abuse should be stopped, such as pay bills related to the substance and clean the 128 
mess made.[11] 129 
  130 
Nowadays, there is a great emphasis on the role the family plays as it is 131 
considered a predictive factor for the drug addict’s behavioural change and adherence 132 
to treatment, favouring the commitment to modify the prejudicial habits previously 133 
adopted by the DU. Sometimes being the principal source of support, they are in an 134 
excellent position to prompt the DU to enter treatment. Since the use of drugs and its 135 
consequences significantly impact not only the individual’s health, but also the well-136 
being of the family as a whole, interventions targeting both have been identified as a 137 
public health priority.[4, 7, 12, 15, 27, 28]  138 
Unfortunately, as the individual’s substance problem progresses, he/she may 139 
become increasingly isolated from the family; consequently, it may be difficult to 140 
engage them later in the treatment process.[3]  141 
Specific family-involved approaches have been developed to help addicted 142 
individuals recognize one’s problem and seek help [3, 4, 8, 11, 12, 16, 18, 24, 28-32]: 143 
- Community Reinforcement Approach: reinforcement should be used to 144 
alter the problematic behaviour; teaches behaviour-change skills to the 145 
CSO; 146 
- Community Reinforcement and Family Training: believes the family can 147 
play a powerful role to persuade a loved one who is resistant to treatment; it 148 
goals to teach family members how to (a) encourage the substance abuser 149 
to evaluate whether or not the behaviour is problematic, (b) support 150 
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abstinence, (c) encourage the engagement in treatment, (d) improve mood, 151 
functioning and, therefore, quality of life of both – significantly more 152 
successful in engaging the users in treatment; 153 
- Johnson Institute Intervention: trains for a confrontation of the user to 154 
show the need for a change; a request that he/she seeks treatment and 155 
consequences for not doing so (the majority of the families do not complete 156 
the program); 157 
- Unilateral Family Therapy: helps family members develop or strengthen 158 
coping skills, improve family functioning and create an environment 159 
conducive to sobriety; 160 
- Multisystemic Family Therapy: assumes substance abuse is influenced by 161 
multiple systems; one of its purposes is to examine each system and their 162 
relationship to the presenting problem; 163 
- Behavioural Couples therapy: teaches how to reward abstinence, 164 
decrease triggers for consuming, decrease behaviours that protect the DU 165 
from adverse consequences and improve their relationship. Better 166 
communication and more cohesive relationships are believed to be a 167 
protective factor for relapse; 168 
- Al-Anon/Nar-Anon Family Groups: the most widely used source of 169 
support for CSOs; not designed to directly make the DU engage in 170 
treatment; it provides support for the family and defends the detachment 171 
and acceptance of one’s inability to control the user behaviour and to reduce 172 
emotional distress. 173 
 174 
 These family/multisystem therapies, believed to be more successful comparing 175 
to the individual ones, share some main goals: (a) improve family coping; (b) 176 
empowerment of the CSOs to positively support the patient’s efforts to eradicate any 177 
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substance abuse and (c) restructure their interaction patterns to promote a better 178 
environment and more cohesive relationships – conducive to long-term stable 179 
abstinence and less probability of relapse.[3, 9, 31] 180 
Having in consideration the importance of the family system in one’s SUD, it 181 
becomes clear that family and friends should be invited to become part of the treatment 182 
and should be able to cope effectively with the user which can lead to better results. 183 
Families can benefit from expressing their own emotional burden and changing 184 
behaviours that can interfere with the recovery of the member with the SUD. Learning 185 
about potential relapse warning signs and how to intervene early if a relapse occurs 186 
can empower family members. To sum up, it is expected that the family members’ 187 
change may promote changes in the attitudes of the drug users.[10, 12, 14] 188 
The new approaches focus not only on the drug user as the previous ones, but 189 
also on the family members and CSOs who deal with the stress and substance related 190 
problems on a daily basis. These mechanisms can help them to become more aware 191 
of their own needs and strengths which can be of great importance to a successful 192 
recovery. Members are taught to increase social behaviours incompatible with 193 
substance use, improve problem solving, enhance communication skills and learn how 194 
to cope and support.[3, 4, 10, 12]  195 
10 
 
2. Defining Codependency  196 
Despite its growing importance, codependency stills represents a controversial and 197 
broad concept, without a universal consensus about its definition which difficult its 198 
generalization and patient’s examination.[3, 15, 33-37] These ambiguous and multiple 199 
meanings suggest that the phenomenon is largely a social construct.[38] Nevertheless, 200 
prefrontal cortex failure to inhibit empathic behaviours can play a role in 201 
codependence.[36] 202 
Codependency (whose prevalence is not well studied) is related to 203 
pathologically excessive involvement and preoccupation - characterized by extreme 204 
dependency - regarding the life of the other, leading to an unhealthy and dysfunctional 205 
relationship; over-zealous helping tending to put other people’s needs ahead of one’s 206 
own, minimizing personal demands.[15, 33-36, 38, 39] 207 
This phenomena can happen to anyone – initially associated with substance abuse, 208 
now related to any problematic behaviours – although it is usually expected with some 209 
specific personality traits (like neuroticism) and environments/backgrounds such as 210 
having alcoholic parents/partners, physical violence in the family, childhood abuse, a 211 
dysfunctional/stressful family environment or gaining responsibilities towards others in 212 
a very young age.[10, 15, 34, 35, 37, 39]  213 
Considered to be a “disease”, this disputed term gained some popularity as 214 
“addictive love” or “pathological altruism" – the aim and motivation of the behaviour is 215 
to promote the welfare of another, but it results in negative consequences to the self 216 
and to the other.[17, 34, 36] The ones suffering from it are believed to perceive 217 
problems in a more stressful way and use less effective coping strategies leading to 218 
vulnerability to experience codependency.[15] 219 
Other articles refer it as an emotional, psychological and behavioural condition with 220 
interpersonal reactivity and obsession that creates self-neglect behaviours and, 221 
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consequently, suffering with an excessive reliance on others for approval and identity 222 
(low self-esteem and sense of self-worth). The individuals are committed to problematic 223 
relationships (besides all the severe social and emotional difficulties) and are incapable 224 
to end them. Usually referring to the female gender, partly due to its cultural role as 225 
caregivers and being inherently more empathic – believed to be more prevalent within 226 
this group.[10, 17, 33-39] 227 
Within these numerous definitions in the literature, there are several core elements 228 
present in many of them [33, 35-37, 39-41]:  229 
- external focusing: extreme focus of one’s attention on the attitudes, 230 
opinions and expectations of others and then fitting one’s own behaviour to 231 
those expectations to obtain approval and esteem; 232 
- self-sacrificing: to put other people’s needs before one’s own (caretaking 233 
and rescuing); 234 
- interpersonal control: deeply believing in one’s capacity to solve other 235 
people’s problems; 236 
- emotional suppression; 237 
- belief in personal powerlessness and other’s powerfulness.  238 
 239 
Research into codependency has been hampered by the lack of instruments to 240 
measure its core components leading to scarce empirical basis.[34, 36] 241 
Developed by Dear & Roberts, the Holyoake Codependency Index (HCI), one of 242 
the scales available to assess codependency, measures codependent traits by asking 243 
the individuals to self-analyse their own characteristics. It is divided in three subscales 244 
“self-sacrifice”, “external focus” and “reactivity” (a reactive stance toward the 245 
problematic behaviour; the respondent perceives his/her quality of life to be contingent 246 
upon the other’s behaviour).[33, 36, 40]  247 
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In other studies, codependency is defined as “an interactional problem, a model 248 
of relationship established early on between the family and the drug user”. A group of 249 
maladaptive adjustments that creates negative emotions (as denial, anger, sadness 250 
and hatred) for the individual experiencing it, who feels out of control and may 251 
(inadvertently) enable the unhealthy and addictive behaviours – even though may 252 
knowing it is not really in the other’s long-term best interest.[3, 10, 13, 34, 36, 37] 253 
These enabling behaviours – a central component of this concept – consist of direct 254 
(such as buying the object of addiction) and indirect (for example, preserving the 255 
reputation, shielding the user from the associated negative consequences) actions 256 
which support one’s drug problem, perpetuating the substance use and reinforcing the 257 
belief in one’s worth.[3, 17, 35]  258 
According to the literature, it is an issue that should be included in the treatment 259 
of addiction in order to improve family functioning. There are three levels of 260 
codependency in clinical practice which change throughout the treatment: low (usually 261 
in the end when there is reconciliation with reality), moderate and high (mostly found in 262 
the beginning). Also there might be a correlation between these levels and the level of 263 
education – the lower the level of education, the higher the codependency.[35, 38, 39, 264 
42] 265 
It is crucial not to stigmatize the individuals who come looking for help regarding 266 
a possible “codependency”, a word with some negative connotations and not the best 267 
one to differentiate it from the normal caregiving, not pathological behaviour – reasons 268 
why some would argue this term should be avoided.[34, 37, 41]   269 
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3. Defining  Motivational Change  270 
According to the Transtheoretical Model [7, 10, 21, 26, 43-46], proposed by 271 
Prochaska and DiClemente, in the 1980s, “health behaviour change involves progress 272 
(over time) through six stages of change”, namely: 273 
- Pre-contemplation; 274 
- Contemplation; 275 
- Preparation; 276 
- Action; 277 
- Maintenance; 278 
- Termination. 279 
 280 
During Pre-contemplation, drug addicts are not committed to cease drug use in 281 
the “foreseeable future” (next 6 months), they are not aware of the dependence or are 282 
dishearten regarding their abilities to change; they initiate treatment only due to family 283 
pressure, court orders or clinical problems arising from the SUD.[7, 26, 43-45]  284 
The Contemplation stage called “behavioural procrastination” is usually 285 
accompanied by ambivalent feelings: users can make associations between their 286 
problems and drug consumption, they start to contemplate the possibility of change 287 
and its pros and cons, but there is still no commitment to engage in the treatment. 288 
People can be stuck in this “decisional balance” for a long time. These first two stages 289 
are the ones associated with the highest dropout rates and relapses.[7, 26, 43, 45] 290 
In the third stage, Preparation, the addict is determined and committed to a 291 
behavioural change in the near future (meaning the following month); however, there is 292 
no real action. Contrary to the previous one, in the fourth stage (Action), drug users, 293 
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aware of their dependence, engage in actions and situations to achieve behavioural 294 
change, such as seeking treatment through their own initiative and showing intentions 295 
to change their lifestyle.[7, 21, 26, 43, 45] 296 
The Maintenance stage is characterized by the persistence of successful 297 
actions in the change direction, towards the end of the process – the new behaviour 298 
becomes normative. During this time, the need to consume drugs gradually decreases 299 
and the challenge is to stay abstinent and avoid everything that could trigger a 300 
recurrence of drug use – preventing a relapse. The most difficult part of this process is 301 
believed to be staying abstinent, not achieving it, and the first three to six months seem 302 
to be the most dangerous time for relapse.[7, 21, 26, 43-45] 303 
In Termination, the last stage, the individuals have complete control over the 304 
dependence - “zero temptation”. The stage of change the individual is at the start of the 305 
intervention is the best predictor of premature dropout and outcome.[43-45] 306 
However, due to an illusory belief of healing, it is common to experience several 307 
relapses throughout the process and return to earlier stages. This process is not linear, 308 
it is rather cyclic so the user can go backwards and exit the treatment at any stage and 309 
several times before achieving the complete remission of a bad habit – usually when 310 
action is taken just because of health problems, without confidence.[21, 24, 26, 43-46] 311 
 312 
 In order to progress through these stages, patients need to put in action several 313 
mechanisms called “processes of change” which need to be emphasised on specific 314 
stages.[21, 43-45] They are defined by ten experiences which require effort and energy 315 
from the DU: 316 
- Consciousness Raising (awareness about the situation); 317 
- Dramatic Relief (emotional arousal); 318 
- Self-reevaluation (cognitive/affective self-image); 319 
15 
 
- Environmental Reevaluation (assessment of how one’s habit affects others); 320 
- Self-liberation (belief and commitment to change); 321 
- Social Liberation (social opportunities);  322 
- Counterconditioning (learning healthier behaviours able to supplant the 323 
problematic ones); 324 
- Stimulus Control; 325 
- Contingency Management (reinforcements – rewards/punishments – 326 
according to the attitudes taken); 327 
- Helping Relationships. 328 
 329 
To sum up: the stages of change are related to when people change; the 330 
processes to how this change happens. Usually, the processes associated with the 331 
insight or awareness (for example, consciousness raising and self-reevaluation) are 332 
present in the early stages and the ones associated with the action (like 333 
counterconditioning and stimulus control) in the later stages.[43, 45]  334 
16 
 
3.1 The Family and the Transtheoretical model  335 
When family members are at the Pre-contemplation stage, change is seen as 336 
an issue only needed for the user. In the Contemplation stage, the family starts 337 
considering their involvement in the member’s drug use and, therefore, their need to 338 
change. In Preparation, the family acknowledges its crucial role and begins the process 339 
of preparing for change - when guidance and help are sought. The Action stage of 340 
change means the family is already involved in actions aimed at changing behaviours. 341 
In the Maintenance stage, the focus is to sustain the healthy behavioural change 342 
already adopted by the family. This approach can lead families to make positive 343 
changes happen through their interactions with the user.[10] 344 
Sometimes treatment is only entered by the families and concerned people 345 
because they want the drug user to engage in it too.[17]   346 
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4. Defining the “system” 347 
One can argue that a SUD can be usually best understood in the entire friends 348 
and family’s functioning context.[3] The DU is sometimes surrounded by a “system” – 349 
composed by family, partner, friends and co-workers – who suffer with the difficulties in 350 
leading with him/her when the SUD is installed. 351 
This network is of great importance to the success of the rehabilitation which is 352 
the reason why many treatment programs also focus in the social recovery (a crucial 353 
part in the treatment but also in relapse and quality of life). This involves several 354 
attitudes such as avoiding contact with high-risk people or events (which might 355 
compromise the recovery), solving relationship problems, developing a new network of 356 
sober and supportive people, resisting social pressures to use substances, engaging in 357 
substance-free activities and mutual support programs, building a new lifestyle and 358 
making amends to those harmed by the disorder.[3, 7, 14]  359 
Social consequences pointed out by family/concerned others are the most 360 
important motivators for a change regarding drug abuse. This “system” can be a helpful 361 
source of support to the person undergoing rehab to reach the goal of a stable, 362 
balanced and substance-free environment.[3, 28]  363 
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5. Final considerations 364 
Worldwide, a substance use disorder is seen as a public health problem. 365 
Hence, it is needed to develop effective techniques to motivate and engage drug users 366 
in treatment. As a familial disease, addiction affects not only the diagnosed individual 367 
but also all intimate relationships and relatives of the addicted person in a chronic but 368 
reversible way; it creates chaos and causes anxiety, disturbance and fear.[24, 28] 369 
According to the codependency model, all members of a family in which one 370 
member has an alcohol or other drug use problem will be affected by it and exhibit its 371 
signs and symptoms. It is further defended that improved family functioning requires 372 
not only the resolution of the affected member’s addiction but also treatment of the 373 
family’s codependency.[35, 40] 374 
Characteristics like low self-esteem, tendency to prioritize others’ needs, 375 
exaggerated caretaking behaviours, obsessive involvement with others are usually 376 
pointed out by addicts’ relatives.[15] Being codependency so frequently present, we 377 
need to give it a major focus during treatment for addicted individuals[39] and an 378 
intervention for the dyad might be the answer to a higher success regarding 379 
rehabilitation programs.  380 
In our days, clinicians are becoming more and more interested in understanding 381 
substance misuse from a systemic perspective rather than its traditional framing as the 382 
challenge of a single individual, involving not only the diagnosed individual but the 383 
whole environment he/she lives in since it is now known this can be used to obtain 384 
better outcomes and improve life quality of both the user and who deals with him/her – 385 
the main goal of any intervention.[3, 27, 28] 386 
Typically, the drug user seeks treatment 6-10 years after the beginning of the 387 
abuse; the earlier the engagement in treatment, the better are the outcomes[4] so it is 388 
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important to reduce this time interval which might happen through the intervention of 389 
CSOs.  390 
Since, after treatment, the family’s lack of adjustment to the member who 391 
changed greatly in the rehabilitation may lead him to relapse, an intervention oriented 392 
to the family is also needed – improving their own health and contributing to the 393 
complete rehabilitation.[4, 10, 35, 39] Besides solving the drug use problem, 394 
interventions provide family members of DUs improved skills to cope with an adverse 395 
situation, reduce depressive symptoms and enhance family functioning – putting both 396 
recoveries in synchrony.[27, 41] 397 
To those emotionally close to the DU who often suffer the most, there are 398 
several benefits of entering treatment such as less vulnerability to stressors and better 399 
coping; also visible decreases in family conflict and physical/mental problems and 400 
increases in relational satisfaction and in self-esteem.[4, 17, 18] 401 
In SUDs, relapse is particularly frequent and some factors are associated with 402 
it, such as low levels of self-efficacy and commitment to abstinence, more problematic 403 
family environments (particularly low cohesion), specific personality traits (like histrionic 404 
and antisocial) and greater life stress/depression; whereas greater social reintegration 405 
and more social/relatives’ support are predictors of better outcomes.[22, 25, 47] 406 
The decision of entering the treatment is usually a difficult one not only for the 407 
DU but also for the CSOs. Before engaging in treatment, all intervenients will need to 408 
be committed to it and determined to do something different to promote well-being. 409 
Usually, to proceed with the treatment, the DU needs to go through several stages of 410 
change, which lead to the complete cessation of drug abuse – this process of change 411 
was described in the Transtheoretical Model of health behaviour change. 412 
In behaviour change, there should be a balance between external pressure and 413 
intrinsic motivation. It is a mistake to believe all people who use alcohol and drugs must 414 
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change alone – there are numerous methods through which loved ones can influence 415 
the drug user, all of them highlighting the power family/friends hold.[28] 416 
According to the literature, compared to participants in the individual treatment 417 
conditions, family-based approaches are clearly more effective therapies. Showing 418 
better rates of abstinence and fewer substance-related problems, greater 419 
improvements in relationship satisfaction and, consequently, decreased risk of 420 
relationship dissolution. Also it is known that when the user is unwilling to seek help, a 421 
family approach can be useful in helping the family cope better and motivating the 422 
users to enter treatment.[3, 27, 31] 423 
 424 
Of course it is not only about commitment and there are some problems that 425 
could arise after entering in the program. One is obviously partner violence that can 426 
arise right after the first changes are introduced at home. Another barrier that could be 427 
pointed out is the lack of therapists’ training since this is a relatively new concept of 428 
treatment. Lastly, there are also important practical and logistical barriers such as 429 
geographical distances between the people involved and difficulties in coordinating 430 
schedules.[3] 431 
In conclusion, since codependency and the consequences for those around 432 
users are important variables for the evolution of a substance use disorder, they could 433 
be used as weapons to achieve the primary goal: the complete rehabilitation and 434 
improvement in quality of life of both the user and the surrounding “system”.   435 
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Future Directions 436 
In this study, alcohol and other drugs were collapsed which can originate a 437 
misconception so it could be useful to investigate them separately. More research is 438 
needed in this area since there is a lack of consistent evidence on substance abuse 439 
related interventions for codependency and the sample sizes of existing studies are 440 
often small which makes it difficult to put the concept in use.[35] More studies 441 
comparing the outcomes of patients with and without a good social environment are 442 
needed in order to support this assumption allowing a broader implementation of these 443 
approaches. Also it could be interesting to analyse ethnic and cultural differences 444 
which are important variables regarding these issues – specially the concept of 445 
codependency.  446 
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